Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility.

Female Genetic Loci / genetics Genetic Predisposition to Disease / genetics Genome-Wide Association Study / methods Genotype Humans Male Melanoma / genetics Phenotype Pigmentation / genetics Polymorphism, Single Nucleotide / genetics Skin Neoplasms / genetics Melanoma, Cutaneous Malignant

Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
05 2020
Historique:
received: 10 07 2019
accepted: 09 03 2020
pubmed: 29 4 2020
medline: 4 8 2020
entrez: 29 4 2020
Statut: ppublish

Résumé

Most genetic susceptibility to cutaneous melanoma remains to be discovered. Meta-analysis genome-wide association study (GWAS) of 36,760 cases of melanoma (67% newly genotyped) and 375,188 controls identified 54 significant (P < 5 × 10

Identifiants

DOI: 10.1038/s41588-020-0611-8 PMID: 32341527 PMC: PMC7255059
pubmed: 32341527
doi: 10.1038/s41588-020-0611-8
pii: 10.1038/s41588-020-0611-8
pmc: PMC7255059
mid: NIHMS1574209
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

494-504

Subventions

Organisme : Cancer Research UK
ID : 10589
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : Cancer Research UK
ID : 29186
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : ZIA CP010200
Pays : United States
Organisme : Cancer Research UK
ID : C490/A16561
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA122838
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00007/10
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA049449
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA049449
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA100264
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA133996
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA083115
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : Wellcome Trust
ID : WT084766/Z/08/Z
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA088363
Pays : United States
Organisme : Cancer Research UK
ID : 10118
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U19 CA148112
Pays : United States

Références

Karimkhani, C. et al. The global burden of melanoma: results from the global burden of disease study 2015. Br. J. Dermatol. 177, 134–140 (2017).
pubmed: 28369739 pmcid: 5575560 doi: 10.1111/bjd.15510
Secretan, B. et al. WHO International agency for research on cancer monograph working group a review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 10, 1033–1034 (2009).
pubmed: 19891056 doi: 10.1016/S1470-2045(09)70326-2
Ford, D. et al. Risk of cutaneous melanoma associated with a family history of the disease. Int. J. Cancer 62, 377–381 (1995).
pubmed: 7635561 doi: 10.1002/ijc.2910620403
Olsen, C. M., Carroll, H. J. & Whiteman, D. C. Familial melanoma: a meta-analysis and estimates of attributable fraction. Cancer Epidemiol. Biomark. Prev. 19, 65–73 (2010).
doi: 10.1158/1055-9965.EPI-09-0928
Olsen, C. M., Carroll, H. J. & Whiteman, D. C. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int. J. Cancer 127, 2430–2445 (2010).
pubmed: 20143394 doi: 10.1002/ijc.25243
Chang, Y. M. et al. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int. J. Cancer 124, 420–428 (2009).
pubmed: 18792098 pmcid: 2656967 doi: 10.1002/ijc.23869
Olsen, C. M., Carroll, H. J. & Whiteman, D. C. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev. Res. 3, 233–245 (2010).
doi: 10.1158/1940-6207.CAPR-09-0108
Bataille, V. et al. Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer Epidemiol. Biomark. Prev. 16, 1499–1502 (2007).
doi: 10.1158/1055-9965.EPI-07-0152
Han, J. et al. A prospective study of telomere length and the risk of skin cancer. J. Invest. Dermatol. 129, 415–421 (2009).
pubmed: 18668136 doi: 10.1038/jid.2008.238
Green, A. C. & Olsen, C. M. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. Acta Derm. Venereol. 95, 923–927 (2015).
pubmed: 26012553 doi: 10.2340/00015555-2148
Kamb, A. et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8, 23–26 (1994).
pubmed: 7987388 doi: 10.1038/ng0994-22
Berwick, M. et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol. Biomark. Prev. 15, 1520–1525 (2006).
doi: 10.1158/1055-9965.EPI-06-0270
Robles-Espinoza, C. D. et al. POT1 loss-of-function variants predispose to familial melanoma. Nat. Genet. 46, 478–481 (2014).
pubmed: 24686849 pmcid: 4266105 doi: 10.1038/ng.2947
Shi, J. et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat. Genet. 46, 482–486 (2014).
pubmed: 24686846 pmcid: 4056593 doi: 10.1038/ng.2941
Palmer, J. S. et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am. J. Hum. Genet. 66, 176–186 (2000).
pubmed: 10631149 doi: 10.1086/302711
Landi, M. T. et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J. Natl. Cancer Inst. 98, 144–145 (2005).
Brown, K. M. et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet. 40, 838–840 (2008).
pubmed: 18488026 pmcid: 2755512 doi: 10.1038/ng.163
Bishop, D. T. et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat. Genet. 41, 920–925 (2009).
pubmed: 19578364 pmcid: 2741419 doi: 10.1038/ng.411
Amos, C. I. et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum. Mol. Genet. 20, 5012–5023 (2011).
pubmed: 21926416 pmcid: 3298855 doi: 10.1093/hmg/ddr415
Barrett, J. H. et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat. Genet. 43, 1108–1113 (2011).
pubmed: 21983787 pmcid: 3251256 doi: 10.1038/ng.959
Macgregor, S. et al. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat. Genet. 43, 1114–1118 (2011).
pubmed: 21983785 pmcid: 3227560 doi: 10.1038/ng.958
Iles, M. M. et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat. Genet. 45, 428–432 (2013).
pubmed: 23455637 pmcid: 3640814 doi: 10.1038/ng.2571
Law, M. H. et al. Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat. Genet. 47, 987–995 (2015).
pubmed: 26237428 pmcid: 4557485 doi: 10.1038/ng.3373
Ransohoff, K. J. et al. Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma. Oncotarget 8, 17586–17592 (2017).
pubmed: 28212542 pmcid: 5392271 doi: 10.18632/oncotarget.15230
Yokoyama, S. et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480, 99–103 (2011).
Bertolotto, C. et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480, 94–98 (2011).
pubmed: 22012259 doi: 10.1038/nature10539
Duffy, D. L. et al. Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways. Nat. Commun. 9, 4774 (2018).
pubmed: 30429480 pmcid: 6235897 doi: 10.1038/s41467-018-06649-5
Zhang, T. et al. Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. Genome Res. 28, 1621–1635 (2018).
pubmed: 30333196 pmcid: 6211648 doi: 10.1101/gr.233304.117
Elder, D. E., Massi, D., Willemze, R. & Scolyer, R. WHO Classification of Skin Tumours (International Agency for Research on Cancer, 2018).
Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).
Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236–1241 (2015).
pubmed: 26414676 pmcid: 4797329 doi: 10.1038/ng.3406
Zhang, Y., Qi, G., Park, J.-H. & Chatterjee, N. Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. Nat. Genet. 50, 1318–1326 (2018).
pubmed: 30104760 doi: 10.1038/s41588-018-0193-x
Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44, 369–375 (2012).
pubmed: 22426310 pmcid: 3593158 doi: 10.1038/ng.2213
Duffy, D. L. et al. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J. Invest. Dermatol. 130, 520–528 (2010).
pubmed: 19710684 doi: 10.1038/jid.2009.258
Duffy, D. L. et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am. J. Hum. Genet. 87, 6–16 (2010).
pubmed: 20602913 pmcid: 2896771 doi: 10.1016/j.ajhg.2010.05.017
Delgado, D. A. et al. Genome-wide association study of telomere length among South Asians identifies a second RTEL1 association signal. J. Med. Genet. 55, 64–71 (2018).
pubmed: 29151059 doi: 10.1136/jmedgenet-2017-104922
Iles, M. M. et al. The effect on melanoma risk of genes previously associated with telomere length. J. Natl. Cancer Inst. 106, dju267 (2014).
pubmed: 25231748 pmcid: 4196080 doi: 10.1093/jnci/dju267
Pickrell, J. K. et al. Detection and interpretation of shared genetic influences on 42 human traits. Nat. Genet. 48, 709–717 (2016).
pubmed: 27182965 pmcid: 5207801 doi: 10.1038/ng.3570
GTEx Consortium Human genomics: the genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).
pmcid: 4547484 doi: 10.1126/science.1262110
Gamazon, E. R. et al. A gene-based association method for mapping traits using reference transcriptome data. Nat. Genet. 47, 1091–1098 (2015).
pubmed: 26258848 pmcid: 4552594 doi: 10.1038/ng.3367
Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat. Genet. 48, 245–252 (2016).
pubmed: 26854917 pmcid: 4767558 doi: 10.1038/ng.3506
Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228–1235 (2015).
pubmed: 26414678 pmcid: 4626285 doi: 10.1038/ng.3404
Visconti, A. et al. Genome-wide association study in 176,678 Europeans reveals genetic loci for tanning response to sun exposure. Nat. Commun. 9, 1684 (2018).
pubmed: 29739929 pmcid: 5940788 doi: 10.1038/s41467-018-04086-y
Choi, J. et al. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. Nat. Genet. 49, 1326–1335 (2017).
pubmed: 28759004 doi: 10.1038/ng.3927
Li, F. P. & Fraumeni, J. F. Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747–752 (1969).
pubmed: 5360287 doi: 10.7326/0003-4819-71-4-747
Curiel-Lewandrowski, C., Speetzen, L. S., Cranmer, L., Warneke, J. A. & Loescher, L. J. Multiple primary cutaneous melanomas in Li–Fraumeni syndrome. Arch. Dermatol. 147, 248–250 (2011).
pubmed: 21339461 doi: 10.1001/archdermatol.2010.428
Beausejour, C. M. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212–4222 (2003).
pubmed: 12912919 pmcid: 175806 doi: 10.1093/emboj/cdg417
Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of senescence. Genes Dev. 24, 2463–2479 (2010).
pubmed: 21078816 pmcid: 2975923 doi: 10.1101/gad.1971610
Aoude, L. G. et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J. Natl. Cancer Inst. 107, dju408 (2015).
pubmed: 25505254 doi: 10.1093/jnci/dju408
Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221–227 (2009).
pubmed: 19151717 pmcid: 4525478 doi: 10.1038/ng.296
Rachakonda, S. et al. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk. Genes Chromosomes Cancer 57, 564–572 (2018).
pubmed: 30203894 doi: 10.1002/gcc.22669
Derheimer, F. A. & Kastan, M. B. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett. 584, 3675–3681 (2010).
pubmed: 20580718 pmcid: 2950315 doi: 10.1016/j.febslet.2010.05.031
Demenais, F. et al. A linkage study between HLA and cutaneous malignant melanoma or precursor lesions or both. J. Med. Genet. 21, 429–435 (1984).
pubmed: 6595409 pmcid: 1049342 doi: 10.1136/jmg.21.6.429
Bale, S. J. et al. Hereditary malignant melanoma is not linked to the HLA complex on chromosome 6. Int. J. Cancer 36, 439–443 (1985).
pubmed: 4044054 doi: 10.1002/ijc.2910360405
Holland, E. A., Beaton, S. C., Kefford, R. F. & Mann, G. J. Linkage analysis of familial melanoma and chromosome 6 in 14 Australian kindreds. Genes Chromosomes Cancer 19, 241–249 (1997).
pubmed: 9258659 doi: 10.1002/(SICI)1098-2264(199708)19:4<241::AID-GCC6>3.0.CO;2-X
Barger, B. O., Acton, R. T., Soong, S. J., Roseman, J. & Balch, C. Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res. 42, 4276–4279 (1982).
pubmed: 6980704
Rovini, D., Sacchini, V., Codazzi, V., Vaglini, M. & Illeni, M. T. HLA antigen frequencies in malignant melanoma patients. A second study. Tumori 70, 29–33 (1984).
pubmed: 6608815 doi: 10.1177/030089168407000105
Hors, J. et al. in Histocompatibility Testing 1984 (ed. Albert, E. D.) 407–410 (Springer, 1984).
Lee, J. E., Reveille, J. D., Ross, M. I. & Platsoucas, C. D. HLA-DQB1* 0301 association with increased cutaneous melanoma risk. Int. J. Cancer 59, 510–513 (1994).
pubmed: 7960221 doi: 10.1002/ijc.2910590413
Muto, M. et al. HLA class I polymorphism and the susceptibility to malignant melanoma. Tissue Antigens 47, 447–449 (1996).
pubmed: 8795150
Kageshita, T. et al. Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. Tissue Antigens 49, 466–470 (1997).
pubmed: 9174138 doi: 10.1111/j.1399-0039.1997.tb02780.x
Bateman, A. C., Turner, S. J., Theaker, J. M. & Howell, W. M. HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 52, 67–73 (1998).
pubmed: 9714476 doi: 10.1111/j.1399-0039.1998.tb03025.x
Lombardi, M. L. et al. Molecular analysis of HLA DRB1 and DQB1 polymorphism in Italian melanoma patients. J. Immunother. 21, 435–439 (1998).
pubmed: 9807738 doi: 10.1097/00002371-199811000-00005
Luongo, V. et al. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens 64, 84–87 (2004).
pubmed: 15191529 doi: 10.1111/j.0001-2815.2004.00250.x
Campillo, J. A. et al. HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis. Immunogenetics 57, 926–933 (2006).
pubmed: 16365741 doi: 10.1007/s00251-005-0065-2
Planelles, D. et al. HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br. J. Dermatol. 154, 261–266 (2006).
pubmed: 16433795 doi: 10.1111/j.1365-2133.2005.06896.x
Jin, Y. et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat. Genet. 48, 1418–1424 (2016).
pubmed: 27723757 pmcid: 5120758 doi: 10.1038/ng.3680
Jin, Y. et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat. Genet. 44, 676–680 (2012).
pubmed: 22561518 pmcid: 3366044 doi: 10.1038/ng.2272
Curran, K. et al. Interplay between Foxd3 and Mitf regulates cell fate plasticity in the zebrafish neural crest. Dev. Biol. 344, 107–118 (2010).
pubmed: 20460180 pmcid: 2909359 doi: 10.1016/j.ydbio.2010.04.023
Thomas, A. J. & Erickson, C. A. FOXD3 regulates the lineage switch between neural crest-derived glial cells and pigment cells by repressing MITF through a non-canonical mechanism. Development 136, 1849–1858 (2009).
pubmed: 19403660 pmcid: 2680109 doi: 10.1242/dev.031989
Kumano, K. et al. Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis. Pigment Cell Melanoma Res. 21, 70–78 (2008).
pubmed: 18353145 doi: 10.1111/j.1755-148X.2007.00423.x
Schouwey, K., Larue, L., Radtke, F., Delmas, V. & Beermann, F. Transgenic expression of notch in melanocytes demonstrates RBP-Jkappa-dependent signaling. Pigment Cell Melanoma Res. 23, 134–136 (2010).
pubmed: 19895548 doi: 10.1111/j.1755-148X.2009.00651.x
Zabierowski, S. E. et al. Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. Stem Cells 29, 1752–1762 (2011).
pubmed: 21948558 pmcid: 3615703 doi: 10.1002/stem.740
Falchi, M. et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 41, 915–919 (2009).
pubmed: 19578365 doi: 10.1038/ng.410
Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117–122 (2005).
pubmed: 16001072 doi: 10.1038/nature03664
Abel, E. V. & Aplin, A. E. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. Cancer Res. 70, 2891–2900 (2010).
pubmed: 20332228 pmcid: 2848900 doi: 10.1158/0008-5472.CAN-09-3139
Weiss, M. B., Abel, E. V., Dadpey, N. & Aplin, A. E. FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma. Mol. Cancer Res. 12, 1314–1323 (2014).
pubmed: 25061102 pmcid: 4163536 doi: 10.1158/1541-7786.MCR-14-0170
Golan, T. et al. Interactions of melanoma cells with distal keratinocytes trigger metastasis via notch signaling inhibition of MITF. Mol. Cell 59, 664–676 (2015).
pubmed: 26236014 doi: 10.1016/j.molcel.2015.06.028
Cronin, J. C. et al. SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis. Cancer Res. 73, 5709–5718 (2013).
pubmed: 23913827 pmcid: 3803156 doi: 10.1158/0008-5472.CAN-12-4620
Guilford, P. et al. E-cadherin germline mutations in familial gastric cancer. Nature 392, 402–405 (1998).
pubmed: 9537325 doi: 10.1038/32918
Hansford, S. et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 1, 23–32 (2015).
doi: 10.1001/jamaoncol.2014.168 pubmed: 26182300
Kim, H. C. et al. The E-cadherin gene (CDH1) variants T340A and L599V in gastric and colorectal cancer patients in Korea. Gut 47, 262–267 (2000).
pubmed: 10896919 pmcid: 1728009 doi: 10.1136/gut.47.2.262
Tang, A. et al. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J. Cell Sci. 107(Pt 4), 983–992 (1994).
pubmed: 8056851 doi: 10.1242/jcs.107.4.983
Hsu, M. Y., Wheelock, M. J., Johnson, K. R. & Herlyn, M. Shifts in cadherin profiles between human normal melanocytes and melanomas. J. Investig. Dermatol. Symp. Proc. 1, 188–194 (1996).
pubmed: 9627715
Study, C. et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat. Genet. 40, 1426–1435 (2008).
doi: 10.1038/ng.262
Wagner, R. Y. et al. Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J. Invest. Dermatol. 135, 1810–1819 (2015).
pubmed: 25634357 doi: 10.1038/jid.2015.25
Padmanaban, V. et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature 573, 439–444 (2019).
pubmed: 31485072 doi: 10.1038/s41586-019-1526-3 pmcid: 7365572
Peña-Chilet, M. et al. Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer 13, 160 (2013).
pubmed: 23537197 pmcid: 3704782 doi: 10.1186/1471-2407-13-160
Law, M. H. et al. Meta-analysis combining new and existing data sets confirms that the TERT-CLPTM1L locus influences melanoma risk. J. Invest. Dermatol. 132, 485–487 (2012).
pubmed: 21993562 doi: 10.1038/jid.2011.322
Antonopoulou, K. et al. Updated field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: the MelGene database. J. Invest. Dermatol. 135, 1074–1079 (2015).
pubmed: 25407435 doi: 10.1038/jid.2014.491
McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283 (2016).
pubmed: 27548312 pmcid: 5388176 doi: 10.1038/ng.3643
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
pubmed: 17701901 pmcid: 1950838 doi: 10.1086/519795
Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
pubmed: 25722852 pmcid: 4342193 doi: 10.1186/s13742-015-0047-8
Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48, 1284–1287 (2016).
pubmed: 27571263 pmcid: 5157836 doi: 10.1038/ng.3656
DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 (1986).
pubmed: 3802833 doi: 10.1016/0197-2456(86)90046-2
Machiela, M. J. & Chanock, S. J. LDassoc: an online tool for interactively exploring genome-wide association study results and prioritizing variants for functional investigation. Bioinformatics 34, 887–889 (2018).
pubmed: 28968746 doi: 10.1093/bioinformatics/btx561
Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
pubmed: 20616382 pmcid: 2922887 doi: 10.1093/bioinformatics/btq340
Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. 8, 1826 (2017).
pubmed: 29184056 pmcid: 5705698 doi: 10.1038/s41467-017-01261-5
Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295 (2015).
pubmed: 25642630 pmcid: 4495769 doi: 10.1038/ng.3211
DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530–1532 (2012).
pubmed: 22539670 pmcid: 3356847 doi: 10.1093/bioinformatics/bts196
Finucane, H. K. et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet. 50, 621–629 (2018).
pubmed: 29632380 pmcid: 5896795 doi: 10.1038/s41588-018-0081-4
Hormozdiari, F. et al. Colocalization of GWAS and eQTL signals detects target genes. Am. J. Hum. Genet. 99, 1245–1260 (2016).
pubmed: 27866706 pmcid: 5142122 doi: 10.1016/j.ajhg.2016.10.003
Stacey, S. N. et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat. Genet. 43, 1098–1103 (2011).
pubmed: 21946351 pmcid: 3263694 doi: 10.1038/ng.926
Chahal, H. S. et al. Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. Nat. Commun. 7, 12510 (2016).
pubmed: 27539887 pmcid: 4992160 doi: 10.1038/ncomms12510
Ostrom, Q. T. et al. Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Sci. Rep. 8, 7352 (2018).
pubmed: 29743610 pmcid: 5943590 doi: 10.1038/s41598-018-24580-z
Melin, B. S. et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat. Genet. 49, 789–794 (2017).
pubmed: 28346443 pmcid: 5558246 doi: 10.1038/ng.3823
Zhou, Y., Wu, H., Zhao, M., Chang, C. & Lu, Q. The Bach family of transcription factors: a comprehensive review. Clin. Rev. Allergy Immunol. 50, 345–356 (2016).
pubmed: 27052415 doi: 10.1007/s12016-016-8538-7
Milovic-Holm, K., Krieghoff, E., Jensen, K., Will, H. & Hofmann, T. G. FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies. EMBO J. 26, 391–401 (2007).
pubmed: 17245429 pmcid: 1783462 doi: 10.1038/sj.emboj.7601504

Auteurs

Maria Teresa Landi (MT)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. landim@mail.nih.gov.
ORCID: 0000-0003-4507-329X

D Timothy Bishop (DT)

Leeds Institute of Medical Research at St James's, Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
ORCID: 0000-0002-8752-8785

Stuart MacGregor (S)

Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
ORCID: 0000-0001-6731-8142

Mitchell J Machiela (MJ)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0001-6538-9705

Alexander J Stratigos (AJ)

Department of Dermatology, Andreas Syggros Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Paola Ghiorzo (P)

Genetics of Rare Cancers, Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy.

Myriam Brossard (M)

Genetic Epidemiology and Functional Genomics of Multifactorial Diseases Team, Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-1124, Université Paris Descartes, Paris, France.

Donato Calista (D)

Department of Dermatology, Maurizio Bufalini Hospital, Cesena, Italy.

Jiyeon Choi (J)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Maria Concetta Fargnoli (MC)

Department of Dermatology & Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Tongwu Zhang (T)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0003-2124-2706

Monica Rodolfo (M)

Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
ORCID: 0000-0002-9196-0298

Adam J Trower (AJ)

Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.

Chiara Menin (C)

Immunology and Molecular Oncology Unit, Venito Institute of Oncology IOV-IRCCS, Padua, Italy.

Jacobo Martinez (J)

Red Valenciana de Biobancos, FISABIO, Valencia, Spain.

Andreas Hadjisavvas (A)

Department of EM/Molecular Pathology & The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

Lei Song (L)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Irene Stefanaki (I)

Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece.

Richard Scolyer (R)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia.
New South Wales Health Pathology, Sydney, New South Wales, Australia.
ORCID: 0000-0002-8991-0013

Rose Yang (R)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Alisa M Goldstein (AM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-7538-3582

Miriam Potrony (M)

Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERER, Barcelona, Spain.
ORCID: 0000-0003-2766-0765

Katerina P Kypreou (KP)

Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece.

Lorenza Pastorino (L)

Genetics of Rare Cancers, Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy.

Paola Queirolo (P)

Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Cristina Pellegrini (C)

Department of Dermatology & Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Laura Cattaneo (L)

Pathology Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Matthew Zawistowski (M)

Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
ORCID: 0000-0002-3005-083X

Pol Gimenez-Xavier (P)

Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERER, Barcelona, Spain.

Arantxa Rodriguez (A)

Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.

Lisa Elefanti (L)

Immunology and Molecular Oncology Unit, Venito Institute of Oncology IOV-IRCCS, Padua, Italy.

Siranoush Manoukian (S)

Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Licia Rivoltini (L)

Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Blair H Smith (BH)

Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
ORCID: 0000-0002-5362-9430

Maria A Loizidou (MA)

Department of EM/Molecular Pathology & The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

Laura Del Regno (L)

Institute of Dermatology, Catholic University, Rome, Italy.
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
ORCID: 0000-0002-3692-629X

Daniela Massi (D)

Section of Anatomic Pathology, Department of Health Sciences, University of Florence, Florence, Italy.

Mario Mandala (M)

Department of Oncology, Giovanni XXIII Hospital, Bergamo, Italy.

Kiarash Khosrotehrani (K)

UQ Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia.
Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Lars A Akslen (LA)

Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Pathology, Haukeland University Hospital, Bergen, Norway.

Christopher I Amos (CI)

Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
ORCID: 0000-0002-8540-7023

Per A Andresen (PA)

Department of Pathology, Molecular Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Marie-Françoise Avril (MF)

Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Dermatologie, Université Paris Descartes, Paris, France.

Esther Azizi (E)

Department of Dermatology, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv, Israel.
Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

H Peter Soyer (HP)

Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.
ORCID: 0000-0002-4770-561X

Veronique Bataille (V)

Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Department of Dermatology, West Herts NHS Trust, Herts, UK.

Bruna Dalmasso (B)

Genetics of Rare Cancers, Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy.

Lisa M Bowdler (LM)

Sample Processing, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Kathryn P Burdon (KP)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
ORCID: 0000-0001-8217-1249

Wei V Chen (WV)

Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Veryan Codd (V)

Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.

Jamie E Craig (JE)

Department of Ophthalmology, Flinders University, Adelaide, South Australia, Australia.

Tadeusz Dębniak (T)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.

Mario Falchi (M)

Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Department of Dermatology, West Herts NHS Trust, Herts, UK.

Shenying Fang (S)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Eitan Friedman (E)

Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Sarah Simi (S)

Section of Anatomic Pathology, Department of Health Sciences, University of Florence, Florence, Italy.

Pilar Galan (P)

Université Paris 13, Equipe de Recherche en Epidémiologie Nutritionnelle (EREN), Centre de Recherche en Epidémiologie et Statistiques, Institut National de la Santé et de la Recherche Médicale (INSERM U1153), Institut National de la Recherche Agronomique (INRA U1125), Conservatoire National des Arts et Métiers, Communauté d'Université Sorbonne Paris Cité, Bobigny, France.
ORCID: 0000-0003-1706-3107

Zaida Garcia-Casado (Z)

Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.

Elizabeth M Gillanders (EM)

Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore, MD, USA.

Scott Gordon (S)

Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
ORCID: 0000-0001-7623-328X

Adele Green (A)

Cancer and Population Studies, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
CRUK Manchester Institute, Institute of Inflammation and Repair, University of Manchester, Manchester, UK.

Nelleke A Gruis (NA)

Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands.

Johan Hansson (J)

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Mark Harland (M)

Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

Jessica Harris (J)

Translational Research Institute, Institute of Health and Biomedical Innovation, Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Queensland, Australia.

Per Helsing (P)

Department of Dermatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Anjali Henders (A)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.

Marko Hočevar (M)

Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Veronica Höiom (V)

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

David Hunter (D)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Christian Ingvar (C)

Department of Surgery, Clinical Sciences, Lund University, Lund, Sweden.

Rajiv Kumar (R)

Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.
ORCID: 0000-0002-6093-0395

Julie Lang (J)

Department of Medical Genetics, University of Glasgow, Glasgow, UK.

G Mark Lathrop (GM)

McGill University and Genome Quebec Innovation Centre, Montreal, Canada.

Jeffrey E Lee (JE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Xin Li (X)

Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA.

Jan Lubiński (J)

International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.

Rona M Mackie (RM)

Department of Medical Genetics, University of Glasgow, Glasgow, UK.
Department of Public Health, University of Glasgow, Glasgow, UK.

Maryrose Malt (M)

Cancer and Population Studies, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Josep Malvehy (J)

Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERER, Barcelona, Spain.

Kerrie McAloney (K)

Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Hamida Mohamdi (H)

Genetic Epidemiology and Functional Genomics of Multifactorial Diseases Team, Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-1124, Université Paris Descartes, Paris, France.

Anders Molven (A)

Department of Pathology, Haukeland University Hospital, Bergen, Norway.
Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Eric K Moses (EK)

Centre for Genetic Origins of Health and Disease, Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Crawley, Western Australia, Australia.

Rachel E Neale (RE)

Cancer Aetiology & Prevention, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Srdjan Novaković (S)

Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Dale R Nyholt (DR)

Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
School of Biomedical Sciences and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
ORCID: 0000-0001-7159-3040

Håkan Olsson (H)

Department of Oncology/Pathology, Clinical Sciences, Lund University, Lund, Sweden.
Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.

Nicholas Orr (N)

Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
ORCID: 0000-0003-2866-942X

Lars G Fritsche (LG)

Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
ORCID: 0000-0002-2110-1690

Joan Anton Puig-Butille (JA)

Biochemistry and Molecular Genetics Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona,CIBERER, Barcelona, Spain.

Abrar A Qureshi (AA)

Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, RI, USA.

Graham L Radford-Smith (GL)

Inflammatory Bowel Diseases, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Department of Gastroenterology and Hepatology, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia.
University of Queensland School of Medicine, Herston Campus, Brisbane, Queensland, Australia.
ORCID: 0000-0002-2047-6239

Juliette Randerson-Moor (J)

Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
ORCID: 0000-0003-0303-0072

Celia Requena (C)

Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.

Casey Rowe (C)

UQ Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia.

Nilesh J Samani (NJ)

Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.

Marianna Sanna (M)

Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Department of Dermatology, West Herts NHS Trust, Herts, UK.

Dirk Schadendorf (D)

Department of Dermatology, University Hospital Essen, Essen, Germany.
German Consortium Translational Cancer Research (DKTK), Heidelberg, Germany.
ORCID: 0000-0003-3524-7858

Hans-Joachim Schulze (HJ)

Department of Dermatology, Fachklinik Hornheide, Institute for Tumors of the Skin, University of Münster, Münster, Germany.

Lisa A Simms (LA)

Inflammatory Bowel Diseases, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Mark Smithers (M)

Queensland Melanoma Project, Princess Alexandra Hospital, The University of Queensland, St Lucia, Queensland, Australia.
Mater Research Institute, The University of Queensland, St Lucia, Queensland, Australia.
ORCID: 0000-0002-8333-8685

Fengju Song (F)

Departments of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P. R. China.

Anthony J Swerdlow (AJ)

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.

Nienke van der Stoep (N)

Department of Clinical Genetics, Center of Human and Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.

Nicole A Kukutsch (NA)

Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands.

Alessia Visconti (A)

Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Department of Dermatology, West Herts NHS Trust, Herts, UK.
ORCID: 0000-0003-4144-2019

Leanne Wallace (L)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.

Sarah V Ward (SV)

Centre for Genetic Origins of Health and Disease, School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Lawrie Wheeler (L)

Translational Research Institute, Institute of Health and Biomedical Innovation, Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Queensland, Australia.

Richard A Sturm (RA)

Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.
ORCID: 0000-0003-1301-0294

Amy Hutchinson (A)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA.

Kristine Jones (K)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA.

Michael Malasky (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA.

Aurelie Vogt (A)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA.

Weiyin Zhou (W)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA.

Karen A Pooley (KA)

Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.

David E Elder (DE)

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Jiali Han (J)

Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA.

Belynda Hicks (B)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA.
ORCID: 0000-0001-8014-4888

Nicholas K Hayward (NK)

Oncogenomics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Peter A Kanetsky (PA)

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
ORCID: 0000-0002-5567-9618

Chad Brummett (C)

Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA.

Grant W Montgomery (GW)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
ORCID: 0000-0002-4140-8139

Catherine M Olsen (CM)

Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
ORCID: 0000-0003-4483-1888

Caroline Hayward (C)

MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
ORCID: 0000-0002-9405-9550

Alison M Dunning (AM)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
ORCID: 0000-0001-6651-7166

Nicholas G Martin (NG)

Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
ORCID: 0000-0003-4069-8020

Evangelos Evangelou (E)

Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.
Department of Epidemiology and Biostatistics, Imperial College London, London, UK.

Graham J Mann (GJ)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, Australia.
John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia.
ORCID: 0000-0003-1301-405X

Georgina Long (G)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Royal North Shore Hospital, Sydney, Australia.

Paul D P Pharoah (PDP)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
ORCID: 0000-0001-8494-732X

Douglas F Easton (DF)

Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
ORCID: 0000-0003-2444-3247

Jennifer H Barrett (JH)

Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
ORCID: 0000-0002-1720-7724

Anne E Cust (AE)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Cancer Epidemiology and Prevention Research, Sydney School of Public Health, Sydney, Australia.

Goncalo Abecasis (G)

Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

David L Duffy (DL)

Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.
Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

David C Whiteman (DC)

Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
ORCID: 0000-0003-2563-9559

Helen Gogas (H)

First Department of Internal Medicine, Laikon General Hospital Greece, National and Kapodistrian University of Athens, Athens, Greece.

Arcangela De Nicolo (A)

Cancer Genomics Program, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

Margaret A Tucker (MA)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Julia A Newton-Bishop (JA)

Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

Ketty Peris (K)

Institute of Dermatology, Catholic University, Rome, Italy.
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Stephen J Chanock (SJ)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-2324-3393

Florence Demenais (F)

Genetic Epidemiology and Functional Genomics of Multifactorial Diseases Team, Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-1124, Université Paris Descartes, Paris, France.
ORCID: 0000-0001-8361-0936

Kevin M Brown (KM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Susana Puig (S)

Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERER, Barcelona, Spain.

Eduardo Nagore (E)

Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.
ORCID: 0000-0003-3433-8707

Jianxin Shi (J)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Mark M Iles (MM)

Leeds Institute for Data Analytics, University of Leeds, Leeds, UK. M.M.Iles@leeds.ac.uk.
ORCID: 0000-0002-2603-6509

Matthew H Law (MH)

Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Matthew.Law@qimrberghofer.edu.au.
ORCID: 0000-0002-4303-8821

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Locus génétiques › Genome-wide association meta-analyses...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Prédisposition génétique à une maladie › Genome-wide association meta-analyses...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Épidémiologie moléculaire › Étude d'association pangénomique › Genome-wide association meta-analyses...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Genome-wide association meta-analyses...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Genome-wide association meta-analyses...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › Genome-wide association meta-analyses...
questionsmedicales.fr › Phénomènes génétiques › Phénotype › Genome-wide association meta-analyses...
questionsmedicales.fr › Phénomènes biologiques › Pigmentation › Genome-wide association meta-analyses...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Polymorphisme de nucléotide simple › Genome-wide association meta-analyses...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › Genome-wide association meta-analyses...